Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of CA-IX,CA9. The page also collects GeneMedi's different modalities and formats products for CA-IX in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CA-IX target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes known. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It may be involved in cell proliferation and transformation. This gene was mapped to 17q21.2 by fluorescence in situ hybridization, however, radiation hybrid mapping localized it to 9p13-p12. [provided by RefSeq, Jun 2014]

Target IDGM-T64567
Target NameCA-IX
Gene ID768
Gene Official NameCA9
Gene AliasCAIX, MN
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index, Immuno-oncology Target


Pre-made CA-IX-specific INN-index biosimilar (antibody&conjugates)-Girentuximab, iodo (124I) girentuximab

Anti-CA-IX therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-ab-245Pre-Made Girentuximab biosimilar, Whole mAb Radiolabelled, Anti-CA9/CA-IX Antibody: Anti-CAIX/MN therapeutic antibodyGirentuximabCA9/CA-IXWhole mAb RadiolabelledINN mab
GMP-Bios-INN-877Pre-Made Iodo (124I) Girentuximab Biosimilar, Radiolabelled Antibody, Anti-CA9/CA-IX Antibody: Anti-CAIX/MN therapeutic antibodyiodo (124I) girentuximabCA9/CA-IXRadiolabelled antibodyINN mab



Pre-made anti-CA-IX inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CA-IX benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CA-IX mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T64567-AbAnti-CA-IX/CA9 monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×